Week of November 29th 2021 | Vol. 10, Issue 47 |
|
|
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events
Quick Links
Contact Information
Managing Director
Business Development
Managing Director
Head of M&A and Capital Advisory
|
|
Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
|
|
For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
|
|
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
|
|
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
|
|
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business
Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America
Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products
Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
|
|
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities.
“Today marks a major milestone for ANI and the many patients who rely on our high-quality, cost-effective medications. With the completion of this acquisition, we bring on board a world-class R&D engine in the generic and 505 (b)(2) sectors, and a highly-compliant U.S. based manufacturing facility, positioning us well for sustainable long-term growth. Novitium has continued to perform in-line or above our investment thesis since deal signing on March 9th with thirteen new product approvals, strong quarter-on-quarter EBITDA growth and a successful FDA GMP inspection completed in July 2021,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
Read the full press release here.
|
|
RECENT INDUSTRY TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
|
|
Pharma & Biotech
13 transactions totaling $959 million
Supplies, Equipment & Services
15 transactions totaling $18 million
Healthcare IT & Managed Care
6 transactions totaling $17,005
Healthcare Facilities & Distributors
13 transactions totaling $61
|
|
Pharma & Biotech
27 transactions totaling $13,915 million
Supplies, Equipment & Services
21 transactions totaling $278 million
Healthcare IT & Managed Care
14 transactions totaling $538 million
Healthcare Facilities & Distributors
7 transactions totaling $76 million
|
|
Pharma & Biotech
4 transactions totaling $190 million
Supplies, Equipment & Services
4 transactions totaling $107
Healthcare IT & Managed Care
1 transaction
Healthcare Facilities & Distributors
0 transactions
|
|
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
|
|
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
|
|
|
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
|
|
November 24, 2021 - Fierce Pharma
Under the deal, Bushu expects to double the volume of Amgen products it makes and packages. It will be in charge of assembly, labeling, packaging and inspection of drugs like Repatha, Evenity, Prolia and Xgeva, with the first supply of those meds pegged to start this year.
November 24, 2021 - Fierce Pharma
The U.S. could have an antiviral pill within weeks. Plus, GreenLight Biosciences and Samsung Biologics are teaming up to manufacture GreenLight's mRNA COVID-19 vaccine candidate.
November 24, 2021 - Fierce Biotech
The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly Therapeutics. The Big Pharma's buy-in comes just a month after Bristol Myers Squibb licensed its sixth drug from the biotech.
November 23, 2021 - Contract Pharma
The new facility will include advanced robotics, high-throughput screening and AI-driven technology. It will support AZ’s focus on specialized and precision medicines and foster the discovery and development of next generation Therapeutics , including nucleotide-based, Gene -editing and Cell therapies.
|
|
Events Hosted or Attended by Bourne Partners
Dates TBD - Charlotte, NC
January 10-14, 2022 - San Francisco, CA
|
|
Early Access Programs can provide rare disease patients with access to critical medicines outside of clinical trials. Check out Tanner’s recent article outlining these opportunities on Patient Worthy: Rare Patient News.
|
|
Key directors will attend World Orphan Drug Congress and several other industry events throughout Nov. and Dec. Let’s connect!
|
|
Welcome to Bourne, let's talk.
Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.
|
|
|
|
|
|
|
